Keightley Amen

Cancer Nursing Today nonprod

Identification of human epidermal growth factor receptor 2 (HER2) status is important in breast cancer diagnosis, prognostication, and treatment planning. Although tremendous strides have been made in detecting this biomarker, there is a need for additional testing methods that are more convenient and less invasive than solid-tissue biopsy, particularly for monitoring patients over the care continuum. A presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting reviewed data from a study that tested the concordance of liquid biopsy with solid tissue biopsy.The researchers recruited 20 patients with stage III or IV breast cancer that was confirmed via solid tissue biopsy to be human epidermal growth factor receptor 2 (HER2)-positive. They collected 8 ml of whole blood from each subject, then applied the LiquidScan system. The procedure isolated circulating tumor cells, then analyzed them via fluorescence in situ hybridization as well automated and visual microscopy. The procedure had 100% concordance with solid-tissue biopsy, as it was able to identify all HER2 positivity.&ldquo;Liquid biopsy may provide a cost effective, sensitive, and non-invasive approach to monitor response,&rdquo; wrote the authors, a group of researchers from the University of California at San Diego and Biofluidica, also in San Diego. They are planning further research.

Liquid Biopsy Shows 100% Concordance with Solid Tissue Biopsy in Recent Study

Conferences

Identification of human epidermal growth factor receptor 2 (HER2) status is important in breast cancer diagnosis, prognostication, and treatment planning.

About Us

Editorial Policy

Authors

Advertising

eNewsletters

Contact Us

Contribute

Calendar of Events

Career Center

Blood Cancers Today

GU Oncology Now

DocWire News

MashupMD

Urban Health Today

Breast Cancer

Colorectal Cancer

GI Cancer

GU Cancer

Gynecologic Cancer Awareness Month

Gyn-Onc

Blood Cancer Awareness Month

GVHD

Leukemia

Lymphoma

Myeloproliferative Neoplasms

Multiple Myeloma

Myelodysplastic Syndrome

Myelofibrosis

Sickle Cell

Hem/Onc

Professional Development

Patient Voice

Lung Cancer

Skin Cancer

Other Tumor Types

News

Treatment

More

Calendar

CARE Award

Best Practices

Expert Interviews

Subscribe